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Abstract
Alzheimer’s disease (AD), an incurable, progressive neurodegenerative disorder, is the most common form of dementia.
Therapeutic options have been elusive due to the inability to deliver proteins across the blood-brain barrier (BBB). In order
to improve the therapeutic potential for AD, we utilized a promising new approach for delivery of proteins across the BBB.
We generated a lentivirus vector expressing the amyloid b-degrading enzyme, neprilysin, fused to the ApoB transport
domain and delivered this by intra-peritoneal injection to amyloid protein precursor (APP) transgenic model of AD. Treated
mice had reduced levels of Ab, reduced plaques and increased synaptic density in the CNS. Furthermore, mice treated with
the neprilysin targeting the CNS had a reversal of memory deficits. Thus, the addition of the ApoB transport domain to the
secreted neprilysin generated a non-invasive therapeutic approach that may be a potential treatment in patients with AD.
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Introduction
Alzheimer’s disease (AD) is an incurable progressive neurode-
generative disorder affecting over 10 million people in the US
alone[1]. This neurological disorder is characterized by wide-
spread neurodegeneration throughout the association cortex and
limbic system, deposition of Ab in the neuropil and around the
blood vessels, and formation of neurofibrillary tangles[2]. In spite
of the considerable progress towards better understanding the
pathogenesis of AD, no effective therapeutic approaches are
currently available. A fundamental problem toward the goal of
developing new therapies for AD has been the difficulty in crossing
the blood brain barrier (BBB)[3].
Experimental treatments for AD include reducing the synthesis
or aggregation of Ab or increasing the clearance of Ab. Recently,
progress has been made towards identifying endopeptidases, which
directly degrade Ab and play an important role in the homeostatic
control of this peptide. Among them, Neprilysin (NEP, also known
as CD10, EC 3.4.24.11)—a zinc metalloendopeptidase—has been
identified as a critical Ab-degrading enzyme in the brain[4,5,6].
Neprilysin has been shown to degrade Ab monomers; however,
the ability of NEP to degrade Ab-oligomers is controversial while
some groups have reported that this endopeptidase breaks down
oligomers[7,8], others have not seen such effects[9,10]. Neprilysin
levels are reduced in the brains of AD patients and a potential
genetic linkage is currently being investigated (reviewed in[11]).
We and other groups have shown that overexpression of NEP
by gene transfer with viral vectors[12,13,14], transgenesis[15], or
induction[16,17,18,19,20] resulted in a reduction in amyloid
pathology.
Viral vector gene delivery of NEP via stereotactic injection into
the CNS has proven to be a viable approach to treating the small
brain of mice or rats; however, scaling up to the size of the human
brain would require numerous injections that would make these
treatments undesirable. An alternative approach for delivery of a
therapeutic protein to the CNS is by transport across the BBB.
Recently, a novel approach was developed for delivering
therapeutic proteins to neurons of the CNS by targeting passage
across the BBB[21]. Fusion of the Apolipoprotein B (ApoB) low-
density lipoprotein (LDL) receptor-binding domain to a targeted
protein allows active transport of the protein across the BBB to the
CNS. The fusion proteins can be taken up by neurons and
astrocytes across the whole brain. To investigate the potential
therapeutic value of a secreted NEP targeted to the CNS, we
generated lentivirus vectors expressing either the wildtype NEP, a
secreted form of the NEP or a secreted form of the NEP fused with
the LDL-receptor binding domain of ApoB and injected them
intra-peritoneally in an amyloid protein precursor (APP) trans-
genic (tg) model of AD-like pathology. We found that ApoBSec-
NEP was efficiently trafficked into the CNS and reduced levels of
Ab and synaptic alterations in the brains of mice. In addition, we
observed improvements in learning and memory just 1 month
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16575after vector delivery. These results suggest a novel, and improved
approach for delivery of an Ab degrading enzyme and other
neuroactive peptides to the CNS for treatment of AD.
Results
The apoB-secreted neprilysin fusion protein is active and
functions similarly to endogenous neprilysin
To determine if the fusion ApoBSecNEP protein and SecNEP
variant proteins were secreted and active, lentiviruses were
produced and used to infect 293T cells. Infected cell lysates and
conditioned media were collected 72 hours after virus infection
and analyzed by western blot. The NEP antibody recognized a
band at ,100 kDa in the lysates of the 293T cells infected with the
LV-NEP, LV-SecNEP and the LV-ApoBSecNEP (Figure S1B).
This band was not observed in uninfected 293T cells or cells
infected with the LV-ApoBGFP virus indicating that NEP is not
endogenously produced by the 293T cells. Conditioned media
contained the secreted NEP reacting band at 100 kDa only in
cultures infected with the LV-SecNEP and LV-ApoBSecNEP
viruses whereas the media from control cells or cells infected with
the LV-NEP did not contain NEP (Figure S1C).
In order to determine if the vectors expressing the fusion NEP
constructs were enzymatically active, cell lysates or conditioned
media samples were incubated with an N-terminus FITC labeled
Ab42 for 24 hours. In this system, NEP activity is detected by the
presence of a 2 kDa band corresponding to the N-terminal
cleavage product of Ab. Lysates of infected 293T cells showed
increased NEP activity from all the NEP vectors tested with the
wildtype NEP displaying a 6 fold increase in Ab cleavage
compared to uninfected 293T cells (Figure 1A). Of particular
interest, the SecNEP and ApoBSecNEP proteins were present at
reduced levels in the lysates of the infected cells, however the NEP
activity was as efficient as wild type NEP with the SecNEP and
50% higher with the ApoBSecNEP (Figure 1C)
Conditioned media from infected cells was subjected to the
same N-terminus FITC labeled Ab cleavage assay (Figure 1B).
Low levels of Ab cleavage activity were observed from uninfected
and LV-NEP infected conditioned media, however as expected,
NEP activity was present in the conditioned media of cells infected
with either the LV-SecNEP or LV-ApoBSecNEP vectors. Ab
cleavage was detected at levels comparable to cell lysates only in
those samples that had the secreted NEP (Figure 1D). The Ab
cleavage was specific to the presence of NEP as the addition of
thiorphan, a NEP specific inhibitor, blocked the formation of the
Ab cleavage product (Figure 1A,B).
To determine if the fusion NEP constructs were active in a cell
based system, differentiated adult rat neural progenitor cells
(NPCs) exposed to Ab were utilized. In this system, differentiated
NPCs treated for 24 hours with Ab showed reduced levels of b-
tubulin immunoreactivity and increased activated caspase 3 levels
indicating Ab induced toxicity (Figure 2A–C). To examine
whether the recombinant NEP could protect the differentiated
NPCs cells from the Ab induced toxicity, cells were infected with
the LV-NEP, LV-SecNEP or LV-ApoBSecNEP and then
challenged with Ab (10 nM) for 24 hours. Cells that expressed
either the wildtype NEP or either of the secreted NEP proteins had
increased b-tubulin immunoreactivity and showed no increase in
Figure 1. Characterization of levels of expression and activity of the ApoBSecNEP fusion protein. 293T cells were infected with LV-NEP,
LV-SecNEP or LV-ApoBSecNEP and 48 hours later analyzed. (A) Representative images of immunoblot of cell lysates probed with anti-Neprilysin
(upper panel) and anti-Ab (lower panel) antibodies. The middle panel illustrates the proteolytic activity against a FITC labeled Ab42. (B) Representative
images of immunoblot and proteolysis of FITC labeled Ab42 with conditioned media. Reactions were collected at 0 or 24 hours in the presence or
absence of the neprilysin inhibitor thiorphan and analyzed with the Versadoc gel imaging system (BioRad). (C) Analysis of levels of neprilysin
immunoreactive bands and proteolysis of FITC labeled Ab42 with cell lysates. (D) Levels of neprilysin immunoreactivity and proteolysis of FITC labeled
Ab42 with conditioned media.
doi:10.1371/journal.pone.0016575.g001
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protein is capable of protecting the NPC cells in vitro.
In conclusion, the lentiviral vectors containing SecNEP and
fusion ApoBSecNEP express the NEP protein and secrete the
protein into the supernatent of infected cells. In addition, the
fusion NEP constructs are active at cleaving the Ab42 protein in a
similar manner to the wildtype NEP and can protect differentiated
NPCs from an extracellular challenge of Ab. The next step was to
determine if the ApoBSecNEP protein traffics into the brain of
APP tg mice and if it reduces the pathology and deficits associated
with amyloid production.
ApoBSecNEP traffics into the CNS of APP tg mice and
accumulates in neurons in the hipoocampus and
neocortex
To determine whether these vectors might be effective at
reducing the levels of Ab in vivo, we delivered 1610
9 tdu of
lentivirus vector to 6 month old APP tg mice via a single intra-
peritoneal injection. One month after injection, mice were
sacrificed and brains were removed for analysis of Ab and NEP.
In order to verify that the ApoBSecNEP molecule trafficked into
the CNS, immunohistochemical analysis was performed. One
month after lentivirus delivery in the periphery, widespread NEP
uptake was detected only in those mice that had received the LV-
ApoBSecNEP injections (Figure 3D-F) whereas only low levels of
NEP were observed in those mice that received LV-SecNep
(Figure 3A–C). Neprilysin was particularly concentrated in the
hippocampus and the lower layers of the cortex and could be
identified in both the soma and axon of neurons. Consistent with
these results and our previous studies[21], control experiments
utilizing a lentiviral vector expressing the ApoB-GFP fusion
protein confirmed that at 30 days after intra-peritoneal injections,
GFP accumulation was detected in the hippocampus (Figure S2).
Analysis of the levels of NEP immunoreactivity (Figure 3G) and
enzyme activity (Figure 3H) showed almost 10 fold more enzyme
in the brains of mice that had received the ApoBSecNEP
compared to those that received SecNEP or control animals.
Interestingly, the levels of NEP enzyme that accumulated in the
CNS of the APP tg mice was significantly greater than in the
brains of nontg mice. Western blot analysis from the CNS
confirmed the immunohistochemical results (Figure S3).
Closer examination of the sections from mice that received the
LV-ApoBSecNEP showed recombinant protein throughout the
hippocampus. In particular, NEP co-localized with NeuN and
MAP2 positive neurons in the CA1 region and dentate gyrus of the
hippocampus (Figure 4). Intracellular recombinant protein
accumulated in the neuronal soma with some extending into the
axons (Figures 3E, 4A–C).
ApoBSecNEP reduces the levels of Ab in APP tg mice
Previous studies have shown that NEP preferentially degrades
monomeric forms of Ab rather than fibrils[9,10]. Thus to evaluate
the effects of ApoBSecNEP on Ab, we dissected the hippocampus
of the mice treated with the lentiviral vectors and analyzed by
immunoblot. Compared to APP tg mice treated with LV-control,
LV-NEP or LV-secNEP, treatment with LV-ApoBSecNEP
resulted in a 60% reduction in the levels of Ab monomer
(Figure 5A,B). In addition, the levels of an Ab immunoreactive
band right above the 4 kDa monomer was noted to be significantly
reduced with the LV-ApoBSecNEP. The identity of this band at
approximately 6 kDa is unclear but might represent a post-
transcriptionally modified version of Ab that is sensitive to NEP
proteolysis. In contrast, no significant effects were observed in the
levels of full length APP (Figure 5A,C).
When the effects of the LV treatments were analyzed by
immunocytochemistry, one month followed intra-peritoneal de-
Figure 2. Neuroprotective effects of the ApoBSecNEP fusion protein from Ab toxicity. Adult rat hippocampal neural progenitor cells were
differentiated into neurons, infected with LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP for 48 hours and then challenged with 10 nM Ab for
24 hours. Neuronal cells were immunostained and analyzed by confocal laser microscopy. (A) Patterns of immunostaining with antibodies against
neprilysin (first column). Comparison of effects of Ab on neuronal morphology and neurite characteristics with an antibody against b-tubulin (second
and third columns). Scale bar =50 mm. (B) Computer aided image analysis of the levels of b-tubulin immunoreactivity in cells infected with the
lentiviruses and treated with vehicle alone or Ab. (C) Levels of activated caspase-3 immunoreactivity (marker of cell injury via pro-apoptotic pathway)
determined by immunocytochemistry and computer aided image analysis in cells infected with the lentiviruses and treated with vehicle alone or Ab.
(D and E) Determinations of levels of neprilysin activity in cell lysates and the conditioned media utilizing an artificial substrate (DAGNPG). * - indicates
statistically significant difference by 1-way ANOVA with poshoc Dunnet’s when compared to vehicle treated control (p,0.05).
doi:10.1371/journal.pone.0016575.g002
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load of Ab immunoreactive plaques in the neocortex and
hippocampus compared to APP tg mice treated with either LV-
control and LV-NEP (Figure 5D–H; 5I–L). The APP tg mice
treated with LV-secNEP displayed a 20% reduction in the load of
Ab immunoreactive plaques in the hippocampus (Figure 5H).
Since NEP favors the cleavage of monomers rather than fibrils,
the reduction in the number of plaques might be driven in part by
the change in ratio between monomeric and aggregated Ab,
howeverotherfactorsmightbeinvolved including increased clearing
by microglia. Consistent with this possibility, double labeling and
confocal microscopy showed that compared to APP tg mice treated
with LV-control, in mice treated with LV-ApoBsecNEP macro-
phage/microglial cells embedded in the plaques displayed abundant
NEP immunoreactivity (Figure 6). Higher resolution and double
labeling analysis confirmed that the cells associated with the plaques
were immmunostained with antibodies against macrophage markers
such as CD68 and CD11b and contained abundant aggregated Ab
immunoreactive material (Figure S4). Taken together, these results
suggest that the ApoBSecNEP might also be taken up by
macrophages and activate these cells to promote amyloid clearance.
In addition to the effects on extracellular Ab, NEP might modify
AD-like pathology by reducing the accumulation of intracellular
APP metabolites such as Ab[22,23]. Increasingly, intracellular Ab
is being recognized as deleterious to the neuron as much or more
than extracellular Ab[23,24,25]. Detection of intracellular Ab by
immunocytochemistry is difficult because of the cross-reactivity of
most antibodies with APP. However, some studies have suggested
Figure 3. Trafficking of the ApoBSecNEP into the CNS of APP tg mice. Vibratome sections from nontg and APP tg mice that received a single
intra-peritoneal injection of LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP were immunostained with an antibody against NEP and analyzed by
laser scanning confocal microscopy. (A, B) Low levels of NEP immunostaining in APP tg mice and (C) nontg mice treated with LV-secNEP (D, E)
Accumulation of NEP immunoreactivity (red) in the neocortex and hippocampus of APP tg mice and (F) to a lower extent in nontg mice treated with
LV-ApoBsecNEP. Areas of neprilysin immunolabeling (white arrows) were enlarged to show localization within neurons (cutouts E, F). Scale bar
=100 mm for A, B and 20 mm for C–F. (G) Computer aided image analysis of levels of neprilysin immunoreactivity expressed as pixel intensity. (H)
Determinations of levels of neprilysin activity in hippocampal homogenates by measuring an artificial substrate cleavage (DAGNPG). * - indicates
statistically significant difference by 1-way ANOVA with poshoc Dunnet’s when compared to mice treated with the LV-Control (p,0.05). n=8 mice
per group.
doi:10.1371/journal.pone.0016575.g003
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helpful [23,24,25]. Immunocytochemical analysis with the mono-
clonal antibody against Ab 1-16 (clone 82E1) showed that
compared to APP tg mice treated with LV-control, LV-NEP or
LV-secNEP, mice treated with LV-ApoBSecNEP displayed a 60%
reduction in the levels of intracellular APP/Ab immunoreactivity
(Figure 5M–Q).
ApoBSecNEP ameliorates the alterations in synaptic
markers in APP tg mice
It has been proposed that Ab neurotoxicity targets the
synapses[7,26,27]. To determine if delivery of the ApoBSecNEP
could correct the synaptic alterations in these mice, immunohis-
tochemical and western blot analysis were performed. Mice that
received the LV-control, LV-NEP or LV-SecNEP had significant-
ly decreased levels of the post-synaptic marker, PSD 95, and the
pre-synaptic marker, SNAP25, comparable to untreated APP tg
mice (Figure 7A–C, E–G). Whereas mice that received the LV-
ApoBSecNEP showed levels of both synaptic proteins comparable
to nontg mice (Figure 7D,H). Similarly, delivery of the
ApoBSecNEP to nontg mice did not appear to affect synaptic
protein levels indicating that accumulation of the soluble neprilysin
did not have a detrimental effect (Figure 7I,J). Consistent with the
immunocytochemical analysis, western blot analysis confirmed
that, compared to APP tg mice that received the LV-control, LV-
NEP or LV-SecNEP, mice that were treated with LV-ApoBSec-
NEP displayed levels of PSD 95 and SNAP25 comparable to
nontg controls (Figure 7K–M).
ApoBSecNEP reverse memory deficits in APP tg mice
The alterations in synaptic markers in APP tg mice have been
associated with memory and learning deficits beginning at 3–6
months of age as measured in the Morris water maze[28]. To
determine if delivery of the ApoBSecNEP could ameliorate these
deficits, APP tg mice were tested one month after intraperitoneal
delivery of either the LV-control, LV-SecNEP or LV-ApoBSec-
NEP vectors. During the training period of the test, all groups of
mice performed similarly at locating the visible platform after 3
days of testing. In the subsequent days of testing (d4-7) with the
platform submerged nontg mice located the platform in the water
pool, with progressively shorter path distances over time
(Figure 8A). Consistently, linear regression analysis showed a
Figure 4. Localization of ApoBSecNEP in hippocampus of APP tg mice. Sections from APP tg mice that received a single intraperitoneal
injection of LV-ApoBSecNEP were double labeled with antibodies against NEP (panels in red) and neuronal markers MAP2 or NeuN (panels in green).
(A–C) Co-localization of NEP with MAP2 in the pyramidal neurons in the CA1 regions of the hippocampus; (D–F) co-localization of NEP with MAP2 in
granular neurons in the dentate gyrus. (G–I) Co-localization of NEP with NeuN in the pyramidal neurons in the CA1 regions of the hippocampus; (J–L)
co-localization of NEP with NeuN in granular neurons in the dentate gyrus. Scale bar =50 mm.
doi:10.1371/journal.pone.0016575.g004
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(Figure 8B). Compared to nontg controls, APP tg mice that
received the LV-control did not show improvements in the spatial
learning with the submerged platform and the path distance in fact
increased over time (Figure 8A) with a positive slope for the linear
regression analysis (Figure 8C). Similarly, the APP tg treated with
LV-secNEP displayed poor performance taking longer distances to
locate the hidden platform for days 4–6, however at day 7
displayed a trend toward an improvement (Figure 8A). However,
the linear regression analysis was not significant (Figure 8D). In
contrast, APP tg mice that received the LV-ApoBSecNEP vector
were able to learn the location of the hidden platform significantly
faster and at a rate similar to nontg mice (Figure 8A). In
concordance, linear regression analysis showed a significant
negative slope when plotting distance over time (Figure 8E).
Taken together, these results suggest that delivery of the
ApoBSecNEP protein to the CNS of APP tg mice has the
capability of ameliorating the synaptic and memory deficits
Figure 5. ApoBSecNEP reduces Ab in the CNS of APP tg mice. Sections from APP tg mice that had received peripheral injections with the
lentiviral vectors were homogenized, fractioned and examined for levels of APP and Ab by western blot. (A) Representative immunoblot probed with
the 82E1 monoclonal antibody displaying the reduction in the levels of Ab in APP tg mice treated with LV-ApoBSecNEP. (B–C) Analysis of immunoblot
for levels of Ab monomers and full length APP. (D–G) Low magnification view of sections from APP tg mice treated with LV-control, LV-NEP, LV-
SecNEP or LV-ApoBSecNEP respectively and immunolabeled with a monoclonal antibody against Ab (82E1) imaged with the laser scanning
microscope. (H) Computer aided image analysis of the % area of the neuropil occupied by Ab immunoreactive deposits. (I–L) Higher magnification
view of the Ab immunoreactive plaques in APP tg mice treated with the various lentiviruses. (M–P) Representative images of the patterns of
intraneuronal APP/Ab immunostaining in the frontal cortex from APP tg mice treated with LV-Control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP
respectively immunolabeled with a monoclonal antibody against Ab (82E1) imaged with the laser scanning microscope. (Q) Image analysis of levels of
intracellular APP/Ab immunostaining. Scale bar =15 mm for I-L and 10 mm for M-P. * - indicates statistically significant difference by 1-way ANOVA
with poshoc Dunnet’s when compared to LV-Control treated animals (p,0.05). n=8 mice per group.
doi:10.1371/journal.pone.0016575.g005
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Development of new approaches for the delivery of neuroactive
peptides and compounds across the BBB is of fundamental
importance for advancing the therapeutics of AD. For the present
study, we showed that the ApoBSecNEP fusion protein was
efficiently produced from the lentiviral vector in peripheral organs,
trafficked into the CNS and reduced levels of Ab and synaptic
alterations in the brains of mice. In contrast to previous methods
for delivery of soluble NEP[29,30], this study utilized a BBB
targeting peptide fused to the soluble protein for transport to the
CNS. We had previously shown that we could deliver a
recombinant protein across the CNS through the use of the
LDL-R binding domain of ApoB[21], however, this is the first
report showing that this approach can be used in a therapeutic
manner to treat a neurodegenerative disease.
Utilizing this unique approach, intra-peritoneal delivery of the
lentivirus vector results in primarily transduction of the liver and
spleen[21,31], with the liver acting as a depot organ for the
production and secretion of the recombinant protein. In this study,
the ApoBSecNEP expressed in the liver was delivered to the blood
stream from where it traffics to the CNS. The ApoB LDL-R
binding domain on the recombinant protein specifically facilitates
transport across the BBB since the SecNEP protein (lacking apoB)
was not present in the CNS following similar vector delivery and
did not mitigated the neuropathogy in the APP tg mice. Delivery
to the CNS by this route resulted in widespread uptake as
evidenced by the immunoreactivity across areas of the CNS
including the hippocampus and the neocortex, that are promi-
nently affected in AD[2,32]. Moreover, our studies showed that
the fusion protein displayed, both in vitro and in vivo enzymatic
activity comparable to the wildtype secNEP.
This activity included cleavage of an artificial specific substrate,
an FITC-tagged Ab 1-42 and the human Ab produced in the brains
from the transgene. Upon examination of the Ab species in the
CNS, we observed a significant reduction in the monomer Ab but
not full length APP. This is consistent with previous studies showing
that NEP favors the degradation of monomeric Ab over fibrillar
species. The effects of the ApoBsecNEP vector on the levels of Ab
oligomers were difficult to determine by western blot given the
proximity of the molecular weight with C-terminus fragments of
APP. Future studies utilizing SELDI-TOF mass spectrometry
analysis will be needed to identify with greater precision trimers
and other Ab multimers in tissues as has been recently done by
Figure 6. ApoBSecNEP co-localizes with activated macrophages at the site of plaques. Sections from APP tg mice that received peripheral
injections with (A–C) LV-control or (D–F) LV-ApoBSecNEP were double labeled with antibodies against Ab (green) and NEP (red) and imaged with the
laser scanning confocal microscope. (G–M) Representative plaque from a mouse treated with LV-ApoBSecNEP displaying co-localization of Ab
immunoreactive material in macrophages/microglia around the plaques labeled with CD68 (red). White arrows indicate areas of co-localization of Ab
and neprilysin or CD68. Scale bar =20 mm for A–F. Scale bar =10 mm for G–M.
doi:10.1371/journal.pone.0016575.g006
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in APP tg mice has been associated with the progressive
accumulation of Ab oligomers[34,35,36,37,38], then it is remark-
able that we observed a recovery in the synaptic and behavioral
deficits in the APP tg mice treated with ApoBsecNEP. One possible
explanation is that even through the levels of existing oligomers
were not affected, because of the reduction in the monomers, the
progressive generation of more oligomers was decreased or it is also
possible that reducing excessive levels of Ab 1–42 might be
beneficial. For example, some studies have shown that in contrast to
Ab 1–40, monomeric Ab 1–42 could reduce synaptic function and
LTP via glutamate receptors[39,40,41]. An alternative possibility as
shown in this study is that the beneficial effects of ApoBsecNEP
might be associated with a decrease in intra-cellular Ab. A growing
number of studies have shown that accumulation of intracellular Ab
could be deleterious[23,24,25,42,43] by triggering aberrant signal-
ing via CREB[44]. Supporting this possibility, previous studies have
shown that NEP ameliorates the deficits in the fly[22] and rodent
models[23] by diminishing Ab from the intracellular compartment.
Although ApoBsecNEP was located in the soma and dendrites of
neurons, it is not clear if the reduced intracellular Ab may be driven
by this source of NEP. It is also plausible that extracellular
ApoBsecNEP is capable of degrading Ab and this shifts the
equilibrium of Ab from the intracellular space to the extracellular
space thus reducing the intracellular accumulation of Ab indirectly.
In addition to the effects on monomeric and intracellular Ab,
we observed that of ApoBsecNEP trafficking into the CNS
reduced the accumulation of amyloid plaques in the APPtg mice.
Given that NEP does not degrade Ab fibrils alternative possibilities
were investigated. Remarkably, the present study showed that
ApoBsecNEP is also taken up by macrophages/microglia around
the plaques and that these cells contained Ab immunoreactive
material, suggesting that NEP activates the macrophages/
microglia to clear the Ab in the plaques. It’s not clear what drives
microglial cells to the site of plaques in mice treated with the
ApoBSecNEP; however, the increased accumulation of NEP with
the plaques may be the signal for increased microglial activation.
Previous studies have shown that monocyte derived macrophages
Figure 7. Trafficking of ApoBSecNEP to the CNS ameliorates synaptic deficits in APP tg mice. Brain sections from APP tg mice that had
received the lentiviral vectors were immunolabeled with monoclonal antibodies against the post-synaptic marker PSD 95 (red) or the pre-synaptic
marker SNAP25 (red) and imaged with the laser scanning confocal microscope. Images are from the frontal-parietal cortex layers 2–3. (A–D)
Representative images from APP tg mice treated with LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP respectively and immunolabeled with a
monoclonal antibody against PSD 95. (E–H) Images from APP tg mice treated with LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP respectively and
immunolabeled with a monoclonal antibody against SNAP25. (I–J) Computer aided image analysis of the % area of the neuropil stained for PSD 95 or
SNAP 25 structures. (K) Representative immunoblot probed with antibodies against PSD 95, SNAP25 and actin. For these analysis the posterior aspect
of the brain containing the cortex and hippocampus was homogenized and the membrane fraction used for the immunoblot. (L–M) Image analysis of
the immunoreactive bands for PSD 95 and SNAP25 expressed as ratio to actin as loading control. Scale bar =5 mm for A–H. * = indicates statistically
significant difference by 1-way ANOVA with poshoc Dunnet’s when compared to LV-control treated animals (p,0.05). n=8 mice per group.
doi:10.1371/journal.pone.0016575.g007
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fibrillar Ab degradation in macrophages was sensitive to lysosomal
and insulin degrading enzyme inhibitors but insensitive to
proteasomal and neprilysin inhibitors[45]. Therefore, it is unlikely
ApoBsecNEP detected in macrophages was directly involved in
the degradation of Ab fibrils but rather it might have increased the
cleavage of neuropeptide substrates that promote leukocyte
migration[46]. NEP has previously been shown to be expressed
by leukocytes and process peptides involved in migration such
bacterial chemotactic peptide N-formylmethionyl-leucyl-phenylal-
anine (fMLP). Inhibition of CD10/NEP on the surface of human
neutrophils (PMNs) in vitro inhibits migration toward this
chemotaxin, suggesting that enzymatic inactivation by NEP
regulates the neutrophil response to fMLP[47].
The accumulation of ApoBSecNEP in the CNS of APPtg mice
was significantly higher than in the non-tg controls. Since the
levels of the targeted receptor on the BBB namely a member of
the LDL receptor family was not different between control and tg
mice then it is possible that other mechanisms might have been
involved. One possibility is that the rate of accumulation of the
recombinant protein in the CNS might depend on the Ab burden
in CNS. Increased trafficking of ApoBsecNEP into the CNS of
APP tg mice might raise questions as to the potential for toxicity.
In addition to peptides involved in chemoattraction, NEP has
been shown to cleave neuroactive peptides such as met-
enkephalin, substance P and neuropepetide Y. We have
previously shown that regulated expression of NEP in the CNS
is neuroprotective and does not result in a deleterious
degradation of neuropeptides or trophic factors[30,48]. More-
over, the present study showed that mice treated with the
ApoBsecNEP displayed improved behavioral performance in
water maze and amelioration of the synaptic pathology. Taken
together these results suggest that targeted delivery of NEP across
the BBB may be a viable therapy for AD. Although the studies
here utilize the lentivirus vector for delivery of the gene for the
recombinant protein to the mouse liver, it is likely that delivery of
the ApoBSecNEP protein by intravenous injection would have
similar effects. Thus, the ApoBSecNEP may be a feasible non-
invasive therapeutic option for reducing the functional deficits
and the accumulation of Ab in AD.
Materials and Methods
Ethics Statement
All experiments described were carried out in strict accordance
with good animal practice according to NIH recommendations,
and all procedures for animal use were approved by the
Institutional Animal Care and Use Committee at the University
of California at San Diego (UCSD) under protocol #S07221.
Lentivirus vector production
The pre-pro trypsin secretory signal was cloned to the 59 of a
vector expressing the human secreted neprilysin (aa 52–750). The
vector was designated LV-SecNEP. The ApoB LDL-R binding
domain (aa 3371- 3409)[21] was cloned with the secreted neprilysin
between thesecretorysignaland the codingsequenceforthe human
neprilysin producing LV-ApoBSecNEP (Figure S1A). As a control
for transported proteins, a virus was generated as described above
with eGFP, pre-pro trypsin secretory signal and the ApoB LDL-R
binding domain (pLV-ApoBGFP). Lentiviruses expressing NEP,
SecNEP, ApoBSecNEP, GFP or ApoBGFP were generated
essentially as described[49]. An empty lentiviral vector (LV-control)
was utilized for comparison purposes and as a control. Titers were
determined by p24 ELISA assay (Perkin Elmer) as described[49].
Neprilysin activity assays
The relative rate of Ab processing by NEP was determined by
using an N-terminal FITC-tagged human Ab (Ab42; rPeptide). For
cell-free assays, 20 mg of cell lysates, 20 ml conditioned cell media
or 100 ng of human recombinant NEP (R&D Systems) was
incubated with 100 mM Tris, pH 7.4, 10 mM ZnCl2, and 33 mM
FITC-labeled Ab in a final volume of 50 ml. Thiorphan (1 mM;
Calbiochem) was used as a NEP-specific protease inhibitor.
Aliquots were taken at 0 and 24 hours, stopped with an equal
volume of 8 M urea, run on 12% SDS-PAGE gels with MES
buffer (Invitrogen), and analyzed with a Versadoc XL imaging
apparatus (Bio-Rad). The proteolytic activity of NEP was
measured as previously described[29] using the substrate 3-
dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly (DAGNPG; Sigma). Cell ly-
sate was incubated with 50 mM DAGNPG and 1 mM captopril (to
inhibit ACE cleavage of DAGNPG) in a volume of 200 mla t3 7 uC.
Figure 8. Effects of peripheral treatment with LV-ApoBSecNEP in water maze performance in APP tg mice. (A) Four weeks after the
intra-peritoneal injections with the LV-control, LV-SecNEP or LV-ApoBSecNEP virus, memory and learning were assessed by the Morris water maze.
Mice were trained on the cued platform on days 1–3 and then tested for spatial learning on days 4–7 followed by a return of the cued platform on
day 8. (B–E) Linear regression analysis showing the slope for the learning curves in the nontg mice and the APP tg mice with LV-control, LV-secNEP
and LV-ApoB-sec-NEP respectively. * = indicates statistically significant difference by 1-way ANOVA with poshoc Dunnet’s when compared to nontg
treated animals (p,0.05). n=8 mice per group.
doi:10.1371/journal.pone.0016575.g008
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then centrifuging. The supernatant was diluted into 50 mM Tris
(pH 7.4) and fluorescence determined using a Victor2 multilabel
plate reader (excitation 342 nm; emission 562 nm).
Lentiviral infection of neuronal progenitor cells and
challenge with Ab
Adult rat hippocampal neural progenitor cells (NPCs) (Chemi-
con) were grown as previously described[50]. Briefly, NPCs were
grown in DMEM/Ham’s F-12 medium containing B27 supple-
ments without Vitamin A (Gibco). Cells were plated onto glass
coverslips and differentiated in DMEM/F12 medium containing
N2 supplements (Gibco) for 4 days. The cells were then infected
with LV-control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP and
after 24 hrs challenged with 10 nM Ab1–42 (American Peptide) for
24 hours. One set of cells were grown in plates for analysis of NEP
activity and protein levels in lysates and conditioned media and
the other set were grown on coverslips and fixed in 4% PFA for
immunohistochemistry. For this purpose, coverslips were immu-
nolabeled with antibodies against NEP (Abcam), neuron specific
tubulin-III (Millipore Corporation) and activated caspase-3 (Cell
Signaling) followed by secondary antibodies tagged with tyramide
red or FITC and imaged with the laser scanning confocal
microscope. Images were analyzed with the NIH Image J program
to assess levels of pixel intensity.
Lentivirus injections into APP tg mice
The APP tg mice used in these studies express mutated human
(h)APP751 under the control of the mThy-1 promoter (mThy1-
hAPP751; line 41). These tg mice are unique in that, compared to
other tg models, amyloid plaques are found in the cortex
beginning at 3 months and in the hippocampus at 4 months of
age[51]. In addition, the mThy1-hAPP751 mice show learning
and memory deficit in the Morris water maze beginning at 6
months of age[28].
Following NIH guidelines for the humane treatment of animals,
briefly, as described[21], APP tg mice or nontg control littermates
(age 6 months) were injected intra-peritoneally with either the LV-
control, LV-NEP, LV-SecNEP or LV-ApoBSecNEP (1610
9
transducing units (tdu)) in a total volume of 200 ml. For each
group 8 mice were included for a total of 32 nontg and 32 APP tg
mice. For control experiments of the recombinant hybrid protein
trafficking into the CNS a subgroup of nontg (n=4 each per
group) and APP tg mice (n=4 each per groups) were injected
intra-peritoneally with LV-GFP or LV-ApoBGFP.
Water maze testing
As previously described[28], in order to evaluate the functional
effects of LV-ApoBSecNEP treatment in mice, groups of APP tg
animals were tested in the water maze. For this purpose, a pool
(diameter 180 cm) was filled with opaque water (24uC) and mice
were first trained to locate a visible platform (days 1–3) and then a
submerged hidden platform (days 4–7) in three daily trials 2–3 min
apart.Micethat failedto find thehidden platformwithin90seconds
were placed on it for 30 seconds. The same platform location was
used for all sessions and all mice. The starting point at which each
mouse was placed into the water was changed randomly between
two alternative entry points located at a similar distance from the
platform. On day 8, another visible platform trial was performed to
exclude differences in motivation and fatigue. Time to reach the
platform (latency), path length, and swim speed were recorded with
a Noldus Instruments EthoVision video tracking system (San Diego
Instruments) set to analyze two samples per second.
Animal maintenance and tissue processing
Four weeks after the lentiviral intra-peritoneal injections, mice
were tested in the water maze and then anesthetized, perfused with
cold saline, and their brains removed. The left hemibrain was
frozen in isopentane cooled in a Histobath (Shandon Lipshaw,
Pittsburgh, PA) and was used for western blot analysis. The right
hemibrain was immersion-fixed in 4% PFA in PBS, pH 7.4. Fixed
hemibrains were serially sectioned at 40 mm with a vibratome
(Leica) for immunocytochemical and LSCM analysis.
Tissue and cell fractionation and western blot analysis
Samples were homogenized and separated into cytosolic
(soluble) and membrane (insoluble) fractions as described[23,38].
Briefly, mouse brain samples (0.1 g) was homogenized in 0.4 ml
of solution containing containing PBS [pH 7.4], 0.32 M sucrose,
50 mM HEPES, 25 mM MgCl2, 0.5 mM DTT, 200 mg/ml
PMSF, 2 mg/ml pepstatin A, 4 mg/ml leupeptin, 30 mg/ml
benzamidine hydrochloride (Calbiochem, San Diego, CA). The
samples were centrifuged at 1,0006 g for 10 minutes at 4uC.
Supernatants were retained and placed into appropriate ultra-
centrifuge tubes and the pellets were re-homogenized in 0.3 ml
of Buffer A and re-centrifuged at 1,0006 g for 10 minutes at
4uC. The second supernatant was collected and combined with
the first supernatant and centrifuged at 100,0006g for one hour
at 4uC. This final supernatant was collected to serve as the
cytosolic fraction and the remaining pellet was resuspended in
0.2 ml of buffer and re-homogenized; this was the membrane
fraction. Protein concentrations were quantified by BCA
(Pierce). Levels of APP and Ab immunoreactivity were
determined in brain homogenates by western blot as described
previously[38,52] utilizing the membrane fractions. Antibodies
against full-length (FL) APP (mouse monoclonal, clone 22C11,
Chemicon), Ab - 82E1 (IBL International) and NEP (mouse
monoclonal, clone 56C6, Abcam) followed by secondary
antibodies tagged with horseradish peroxidase (HRP) (Santa
Cruz Biotechnology) were used and then visualized by enhanced
chemiluminescence and analyzed with a Versadoc XL imaging
apparatus (Bio-Rad). Analyses of actin levels were used as a
loading control.
Analysis of Ab and plaque load by immunocytochemistry
To evaluate the amyloid plaque load, briefly as previously
described[28], vibratome sections were incubated overnight at 4uC
with the mouse monoclonal antibody against Ab (clone 82E1, IBL
international) followed by fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG (Vector Laboratories). The FITC-
labeled sections were imaged with the laser scanning confocal
microscope (LSCM, MRC1024, BioRad) as described previous-
ly[27]. Digitized images were analyzed with the NIH Image 1.43
program to determine the percent area of the neuropil occupied
by Ab-immunoreactive deposits in the frontal cortex and
hippocampus. To evaluate effects on intracellular Ab, sections
were immunolabeled with the mouse monoclonal antibody against
Ab (clone 4G8; Senetek) and with the antibody against the N-
terminus of Ab (aa 1–16; clone 82E1; Immunobiological
Llaboratorie Co.) followed by incubation with secondary biotiny-
lated anti-mouse IgG and then ABC and DAB. Sections were
transferred to SuperFrost slides (Fisher Scientific) and mounted
under glass coverslips with anti-fading media (Vector Laborato-
ries). All sections were processed under the same standardized
conditions. Three immunolabeled sections were analyzed per
mouse and the average of individual measurements was used to
calculate group means.
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neurodegeneration
To verify the expression levels of NEP, vibratome sections were
immunolabeled with a monoclonal antibody against NEP (CD10,
Abcam) and detected with the Tyramide Signal Amplification
TM-
Direct (Red) system (NEN Life Sciences,). To evaluate the co-
localization of NEP, double immunocytochemical analysis was
performed as previously described[53]. For this purpose, vibra-
tome sections were immunolabeled with a monoclonal antibody
against NEP (Abcam) detected with the Tyramide Signal
Amplification
TM-Direct (Red) system (NEN Life Sciences) and
the mouse monoclonal antibodies against NeuN (Millipore),
MAP2 (Millipore) and Ab (clone 82E1) detected with FITC-
conjugated secondary antibodies (Vector Laboratories)[53]. Addi-
tional co-localization studies were performed with antibodies
against Ab (clone 82E1) and microglia/macrophage markers Iba-1
(Wako), CD68 (Abcam) and CD11b (Abcam). All sections were
processed simultaneously under the same conditions, and
experiments were performed twice to assess reproducibility.
Sections were imaged with a Zeiss 63X (N.A. 1.4) objective on
an Axiovert 35 microscope (Zeiss) with an attached MRC1024
LSCM system (BioRad)[53]. To confirm the specificity of primary
antibodies, control experiments were performed where sections
were incubated overnight in the absence of primary antibody
(deleted) or preimmune serum and primary antibody alone.
The integrity of the neuronal structure was evaluated as
previously described[28,54]; briefly, blind-coded, 40 mm thick
vibratome sections from mouse brains fixed in 4% paraformalde-
hyde were immunolabeled with the mouse monoclonal antibodies
against SNAP25 (synaptic marker, Millipore) and PSD95
(postsynaptic marker, Abcam). After overnight incubation, sections
were incubated with the Tyramide Signal Amplification
TM-Direct
(Red) system (NEN Life Sciences) transferred to SuperFrost slides
(Fisher Scientific) and mounted under glass coverslips with anti-
fading media (Vector Laboratories). All sections were processed
under the same standardized conditions. The immunolabeled
blind-coded sections were serially imaged with the LSCM
(MRC1024, BioRad) and analyzed with the Image 1.43 program
(NIH), as previously described[55]. For each mouse, a total of 3
sections were analyzed and for each section, 4 fields in the frontal
cortex and hippocampus were examined. Results were expressed
as percent area of the neuropil occupied.
Statistical analyses
Analyses were carried out with the StatView 5.0 program (SAS
Institute Inc., Cary, NC). Differences among means were assessed by
one-way ANOVA with post-hoc Dunnett’s or Tukey-Kramer tests.
A l lv a l u e si nt h ef i g u r e sa r ee x p r e s s e da sm e a n s6SEM. Comparisons
between 2 groups were done with the unpaired two-tailed Student’s t-
test.Correlationstudieswerecarried out bysimpleregressionanalysis
and the null hypothesis was rejected at the 0.05 level.
Supporting Information
Figure S1 Characterization of lentiviral vectors containing the
neprilysin constructs. (A) Diagrammatic representation of the
secreted ApoBSecNEP cDNA inserted into the 3
rd generation
lentivirus vector. (B) Immunoblot analysis for expression levels of
NEP, GFP and actin from the LV-control, LV-NEP, LV-SecNEP,
LV-ApoBSecNEP and LV-ApoBGFP vectors. The 293T cells
were infected and 24 hrs later analysis were performed with cell
lysates (20 mg, CL) and conditioned media (20 ml, CM). (C–G)
B103 neuronal cells infected with the lentivirus vectors and
immunostained for expression of NEP (C–F) or visualized for GFP
expression (G). Scale bars =25 mm.
(TIF)
Figure S2 Patterns of ApoBGFP distribution in the CNS
following peripheral delivery. Lentiviral vectors were delivered by
intra-peritoneal injection to non-tg mice and 4 weeks later brains
were visualized for the accumulation of GFP protein. (A, B) Low
power view of the GFP distribution in the neocortex and
hippocampus for LV-control or LV-ApoBGFP vectors respectively
(Scale bar =200 mm forA,B).(C,D)High power demonstrating the
accumulation of the ApoBGFP in the dentate granular cells of the
hippocampus (Scale bar =20 mm for C, D). n=4 mice per group.
(TIF)
Figure S3 Immunoblot analysis of the levels of neprilysin
accumulation in the CNS following intra-peritoneal delivery of
LV-ApoBSecNEP. The posterior cortex and hippocampus from
each mouse were dissected and homogenized. (A) Representative
immunoblot with total protein from the CNS following intra-
peritoneal delivery of LV-control, LV-NEP, LV-SecNEP or LV-
ApoBSecNEP respectively analyzed with antibodies against NEP
and actin. (B) Computer aided image analysis of the NEP
immunoreactive band for nontg and APP tg mice that received
the lentiviral vectors (B). * = indicates statistically significant
difference by 1-way ANOVA with poshoc Dunnet’s when
compared to nontg treated animals (p,0.05). n=8 mice per group.
(TIF)
Figure S4 Co-localization of Ab with macrophage/microglial cell
markers in APP tg mice treated with LV-ApoBSecNEP. For these
studies vibratome sections from APP tg mice were double labeled
with antibodies against Ab (green), or the microglial markers, Iba1
(red) or CD11b (red) and analyzed with the laser scanning confocal
microscope. DAPI (blue) was used to visualize nuclei. Images are
from plaques distributed inthehippocampus. (A–F)Doublelabeling
analysis with antibodies against Ab and Iba1 in mice treated with
LV-control or LV-ApoBSecNEP respectively. (G–L) Double
labeling analysis with antibodies against Ab and CD11b in mice
treated with LV-control or LV-ApoBSecNEP respectively. Arrows
indicate areas of colocalization. Scale bar =50 mm.
(TIF)
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